CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 24 enrolled
Drug / intervention
Pioglitazone +1 moredrug
Likely dose
Pioglitazone 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00656851
NCT00656851N/ACompleted

Myocardial Function, Free Fatty Acid and Glucose Metabolism in HIV Metabolic Syndrome

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·interventional·Posted Apr 11, 2008·Updated Aug 28, 2013

In Brief

A clinical study evaluating Pioglitazone and Exercise Training for HIV Infections and 4 related conditions. Completed, enrolled 24 participants across 1 site.

Detailed Summary

We hypothesize that the hearts of HIV+ people with The Metabolic Syndrome use and oxidize fats and sugars inappropriately, and that this may impair the heart's ability to pump blood. We hypothesize that exercise training or pioglitazone (Actos) will improve fat and sugar metabolism in the hearts of HIV+ people with The Metabolic Syndrome. This study will advance our understanding of cardiovascular disease in HIV+ people, and will test the efficacy of exercise training and pioglitazone for improving insulin resistance, heart metabolism and heart function in this at risk population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 11, 2008
Enrollment StartSep 1, 2005
Primary CompletionAug 1, 2009
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 18.2 years ago

Interventions

Pioglitazonedrug

30mg/day for 16 weeks

Exercise Trainingbehavioral

Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks